relapsed or refractory chronic lymphocytic leukaemia progression after 12 months vs. 68% for comparators AstraZeneca s Calquence (acalabrutinib), a next-generation, selective Bruton s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]). The approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from the ASCEND Phase III trial and a Phase I trial in Japanese patients, showing Calquence monotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus a standard treatment of rituximab, a monoclonal antibody, combined with the physician s choice of idelalisib, a PI3-kinase inhibitor or bendamustine, a chemotherapy.
Coronavirus live updates: US surpasses 25 million cases
kneb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kneb.com Daily Mail and Mail on Sunday newspapers.
Coronavirus live updates: Cases falling week-over-week in most states
midutahradio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from midutahradio.com Daily Mail and Mail on Sunday newspapers.